^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF V600E + KRAS G12R

    i
    Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1, KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS
    Entrez ID:
    3845; 673
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    11ms
    Efficacy of Combined Encorafenib and Binimetinib Treatment for Erdheim-Chester Disease Harboring Concurrent BRAFV600E and KRASG12R Mutations: A Case Report. (PubMed, Cancer Rep (Hoboken))
    This case represents a unique presentation of ECD with concurrent BRAFV600E and KRASG12R mutations. Combination therapy with encorafenib and binimetinib targeting each clone resulted in a remarkable therapeutic effect and was well-tolerated. This is the first reported case of ECD treated with encorafenib and binimetinib. The combination therapy with BRAF and MEK inhibitors is one of the rational treatment options for cases of ECD with a suspicion of multiple clones.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
    |
    BRAF V600E • KRAS mutation • BRAF V600 • KRAS G12R • KRAS G12 • BRAF V600E + KRAS G12R
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)